Applications
Vaccines
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Infectious Disease
Immunology
The technology in focus involves monoclonal antibody CI.11B11.B4.C4, a pioneering biological tool designed to target and bind with high specificity to both isoforms of mouse APOBEC3, mA3 and mA3d5. APOBEC3 proteins play a crucial role in innate immune defense against retroviruses by inducing hypermutation in the viral genome, thereby hindering viral replication and infection. Developed by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, this antibody serves as a vital research tool in the study of viral-host interactions, offering potential breakthroughs in the understanding and suppression of retroviral diseases. Recognized for its utility in various assays, including Western blot and ELISA, the technology stands out as a prototype, ready for licensing as a biological material without the need for additional development or capital investment. This approach aligns with NIH's policy favoring the use of research tools that facilitate broad scientific advancement over pursuing patent protection.
Commercial Applications
Monoclonal antibody CI.11B11.B4.C4 presents significant potential in advancing retroviral research and therapy development. It enables precise studies of the APOBEC3 protein's role in inhibiting viral replication, facilitating the discovery of novel antiviral strategies and diagnostics. This antibody is instrumental in developing targeted treatments and vaccines, particularly against retroviruses like HIV. Its specificity also makes it a valuable tool in pharmaceutical research, accelerating drug discovery and efficacy testing. CI.11B11.B4.C4's applications extend across academic and pharmaceutical fields, underscoring its importance in the fight against viral diseases.
Competitive Advantages
The monoclonal antibody CI.11B11.B4.C4 offers a unique competitive advantage by precisely targeting mouse APOBEC3 proteins, crucial for studying retroviral defense mechanisms. Its specificity minimizes cross-reactivity, enhancing research accuracy. Developed by the NIH and NIAID, it boasts credibility, making it highly attractive to researchers and pharmaceutical companies focused on retroviral therapy advancements. CI.11B11.B4.C4 stands out as a pivotal research tool, facilitating groundbreaking discoveries in virology and immunology.
